Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million

Reuters03-19

Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million

Biofrontera published a financial results press release reporting record Q4 and FY 2025 results and a business update.
Q4 revenue rose 36% to USD 17.1 million, while gross margin expanded 24.4 percentage points to 82.4% due to the shift away from the prior transfer pricing model after the Biofrontera AG transaction.
Q4 operating income was USD 4.56 million and net income was USD 5.64 million.
FY revenue increased 12% to USD 41.71 million, and FY gross margin rose 23.6 percentage points to 73.7% as related-party cost of goods sold fell 43% following the move to a lower earnout structure.
Management said the company expects the full annualized benefits of the new cost structure in 2026 and is targeting sustained profitability and cash flow breakeven in 2026; it also cited a PDUFA date for superficial basal cell carcinoma in September 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190925PRIMZONEFULLFEED9675280) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620225148?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 21:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620225148","market":"fut","top_or_hot":-1,"title":"Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Biofrontera published a financial results press release reporting record Q4 and FY 2025 results and a business update.\n        </li>\n<li>\n          Q4 revenue rose 36% to USD 17.1 million, while gross margin expanded 24.4 percentage points to 82.4% due to the shift away from the prior transfer pricing model after the <a href=\"https://laohu8.com/S/BFFTF\">Biofrontera AG</a> transaction.\n        </li>\n<li>\n          Q4 operating income was USD 4.56 million and net income was USD 5.64 million.\n        </li>\n<li>\n          FY revenue increased 12% to USD 41.71 million, and FY gross margin rose 23.6 percentage points to 73.7% as related-party cost of goods sold fell 43% following the move to a lower earnout structure.\n        </li>\n<li>\n          Management said the company expects the full annualized benefits of the new cost structure in 2026 and is targeting sustained profitability and cash flow breakeven in 2026; it also cited a PDUFA date for superficial basal cell carcinoma in September 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190925PRIMZONEFULLFEED9675280) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 21:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Biofrontera published a financial results press release reporting record Q4 and FY 2025 results and a business update.\n        </li>\n<li>\n          Q4 revenue rose 36% to USD 17.1 million, while gross margin expanded 24.4 percentage points to 82.4% due to the shift away from the prior transfer pricing model after the <a href=\"https://laohu8.com/S/BFFTF\">Biofrontera AG</a> transaction.\n        </li>\n<li>\n          Q4 operating income was USD 4.56 million and net income was USD 5.64 million.\n        </li>\n<li>\n          FY revenue increased 12% to USD 41.71 million, and FY gross margin rose 23.6 percentage points to 73.7% as related-party cost of goods sold fell 43% following the move to a lower earnout structure.\n        </li>\n<li>\n          Management said the company expects the full annualized benefits of the new cost structure in 2026 and is targeting sustained profitability and cash flow breakeven in 2026; it also cited a PDUFA date for superficial basal cell carcinoma in September 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/BFRI\">Biofrontera Inc</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190925PRIMZONEFULLFEED9675280) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbK9jVK:1","article_id":"2620225148","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620225148","pubTimestamp":1773926744,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Biofrontera published a financial results press release reporting record Q4 and FY 2025 results and a business update.Q4 revenue rose 36% to USD 17.1 million, while gross margin expanded 24.4 percentage points to 82.4% due to the shift away from the prior transfer pricing model after the Biofrontera AG transaction.Q4 operating income was USD 4.56 million and net income was USD 5.64 million.FY revenue increased 12% to USD 41.71 million, and FY gross margin rose 23.6 percentage points to 73.7% as related-party cost of goods sold fell 43% following the move to a lower earnout structure.Management said the company expects the full annualized benefits of the new cost structure in 2026 and is targeting sustained profitability and cash flow breakeven in 2026; it also cited a PDUFA date for superficial basal cell carcinoma in September 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BFRI":"Biofrontera Inc","BK4588":"碎股","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4112":"金融交易所和数据","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4007":"制药","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Biofrontera 2025年第四季度毛利率跃升24.4个百分点至82.4%，收入增长36%至1,710万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BFRI":0.9},"content_text":"Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million\n    \n\n\n          Biofrontera published a financial results press release reporting record Q4 and FY 2025 results and a business update.\n        \n\n          Q4 revenue rose 36% to USD 17.1 million, while gross margin expanded 24.4 percentage points to 82.4% due to the shift away from the prior transfer pricing model after the Biofrontera AG transaction.\n        \n\n          Q4 operating income was USD 4.56 million and net income was USD 5.64 million.\n        \n\n          FY revenue increased 12% to USD 41.71 million, and FY gross margin rose 23.6 percentage points to 73.7% as related-party cost of goods sold fell 43% following the move to a lower earnout structure.\n        \n\n          Management said the company expects the full annualized benefits of the new cost structure in 2026 and is targeting sustained profitability and cash flow breakeven in 2026; it also cited a PDUFA date for superficial basal cell carcinoma in September 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biofrontera Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190925PRIMZONEFULLFEED9675280) on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620225148","isCrawlerRequest":true}